Amanda J. P.
- Country
- Spain
- Department
- Endocrinology and Nutrition Department
Research Overview
- Evaluation of Subcutaneous ISIS 678354 Sodium Salt in Patients with Familial Chylomicronemia Syndrome: An Open-Label Extension Study
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
- An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (SHTG)
Data & Insights
Has run more than one trial at 88 of 450 partner sites.
Specializations
Metabolic Disorders
This investigator specializes in the treatment and research of Familial Chylomicronemia Syndrome (FCS), a rare genetic metabolic disorder affecting lipid metabolism.
- Lipid Disorders
- Genetic Metabolic Conditions
- Triglyceride Management
The investigator's work centers on developing therapeutic approaches for managing severe hypertriglyceridemia in patients with genetic lipid disorders.
Therapeutic Innovation
The research focus includes evaluating novel therapeutic agents targeting apoC-III regulation for rare metabolic conditions.
- Novel Therapeutic Approaches
- Long-term Treatment Strategies
- Patient Monitoring Methods
Their work extends to investigating open-label therapeutic interventions for patients with severe genetic lipid disorders.
Clinical Outcomes
The investigator studies the effects of therapeutic interventions on fasting triglyceride levels in patients with genetic metabolic disorders.
- Biomarker Analysis
- Treatment Response Assessment
- Long-term Safety Monitoring
Their research encompasses comprehensive evaluation of clinical outcomes in patients with rare genetic disorders affecting lipid metabolism.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.